Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Fosphenytoin | The serum concentration of Fosphenytoin can be decreased when it is combined with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Raltitrexed | The therapeutic efficacy of Raltitrexed can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Sulfasalazine | The serum concentration of (6S)-5,6,7,8-tetrahydrofolic acid can be decreased when it is combined with Sulfasalazine. |
| Phenytoin | The serum concentration of Phenytoin can be decreased when it is combined with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Glucarpidase | The serum concentration of the active metabolites of (6S)-5,6,7,8-tetrahydrofolic acid can be reduced when (6S)-5,6,7,8-tetrahydrofolic acid is used in combination with Glucarpidase resulting in a loss in efficacy. |
| Phenobarbital | The serum concentration of Phenobarbital can be decreased when it is combined with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Primidone | The serum concentration of Primidone can be decreased when it is combined with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Pyrimethamine | The therapeutic efficacy of Pyrimethamine can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Dapsone | The therapeutic efficacy of Dapsone can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Methotrexate | The therapeutic efficacy of Methotrexate can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Pemetrexed | The therapeutic efficacy of Pemetrexed can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Proguanil | The therapeutic efficacy of Proguanil can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Trimetrexate | The therapeutic efficacy of Trimetrexate can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Piritrexim | The therapeutic efficacy of Piritrexim can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Metoprine | The therapeutic efficacy of Metoprine can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Iclaprim | The therapeutic efficacy of Iclaprim can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Pralatrexate | The therapeutic efficacy of Pralatrexate can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Aminopterin | The therapeutic efficacy of Aminopterin can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Lometrexol | The therapeutic efficacy of Lometrexol can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Nolatrexed | The therapeutic efficacy of Nolatrexed can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Brodimoprim | The therapeutic efficacy of Brodimoprim can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Cycloguanil | The therapeutic efficacy of Cycloguanil can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Valproic acid | The serum concentration of (6S)-5,6,7,8-tetrahydrofolic acid can be decreased when it is combined with Valproic acid. |
| Colestipol | The serum concentration of (6S)-5,6,7,8-tetrahydrofolic acid can be decreased when it is combined with Colestipol. |
| Carbamazepine | The serum concentration of (6S)-5,6,7,8-tetrahydrofolic acid can be decreased when it is combined with Carbamazepine. |
| Fluorouracil | The risk or severity of adverse effects can be increased when (6S)-5,6,7,8-tetrahydrofolic acid is combined with Fluorouracil. |
| Flucytosine | The risk or severity of adverse effects can be increased when (6S)-5,6,7,8-tetrahydrofolic acid is combined with Flucytosine. |
| Capecitabine | The risk or severity of adverse effects can be increased when (6S)-5,6,7,8-tetrahydrofolic acid is combined with Capecitabine. |
| 5-fluorouridine | The risk or severity of adverse effects can be increased when (6S)-5,6,7,8-tetrahydrofolic acid is combined with 5-fluorouridine. |
| Uracil | The risk or severity of adverse effects can be increased when (6S)-5,6,7,8-tetrahydrofolic acid is combined with Uracil. |
| Tegafur | The risk or severity of adverse effects can be increased when (6S)-5,6,7,8-tetrahydrofolic acid is combined with Tegafur. |
| Doxifluridine | The risk or severity of adverse effects can be increased when (6S)-5,6,7,8-tetrahydrofolic acid is combined with Doxifluridine. |
| Pafolacianine | (6S)-5,6,7,8-tetrahydrofolic acid may decrease effectiveness of Pafolacianine as a diagnostic agent. |